Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses ...

The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium’s existing network in ...

ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials ...

This is the second part of a three-part series written by Carolyn Krause. Many of the elements were synthesized using an Oak ...

The periodic table was initially constructed from naturally occurring elements based on similarities in their chemistry, and ...

But the conversation also covered the impact of AI on work which was considered from various perspectives. Carolyn Hicks said ...

About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe.

Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium's existing network in geographies where Curium is not present today Add SPECT ...

Try refreshing your browser, or tap here to see other videos from our team. Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol ...